JBM (Healthcare) Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag

JBM (Healthcare) (HKG:2161) Full Year 2025 Results

Key Financial Results

• Revenue: HK$782.3m (up 21% from FY 2024).
• Net income: HK$197.3m (up 51% from FY 2024).
• Profit margin: 25% (up from 20% in FY 2024). The increase in margin was driven by higher revenue.
• EPS: HK$0.24 (up from HK$0.15 in FY 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

JBM (Healthcare) EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 20%.

The primary driver behind last 12 months revenue was the Proprietary Chinese Medicines segment contributing a total revenue of HK$405.4m (52% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to HK$122.5m (57% of total expenses). Explore how 2161's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 8.3% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on JBM (Healthcare)'s balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.